Overview

A global top 20 biopharma company retained RxC International for support in developing their Life Cycle Plan for a novel MS drug developed for Relapsing / Remitting MS patients.

Approach

RxC International addressed key elements for this life cycle strategy engagement including:

• Evaluating target patient segments for the client’s new therapy to identify which segments were most likely to create value

• Developing Life Cycle Management strategies and tactics based on the drug's unique mechanism of action and evolving treatment paradigms within the MS space

• Completing a comprehensive analysis of potential life cycle opportunities; identified nine high potential strategic launch choices from clinical, regulatory, IP and commercial standpoints

Results

RxC International assisted the client in identifying the most attractive life cycle management opportunity based on extensive qualitative and quantitative analysis as well as financial modeling that included mapping out key time points for the most profitable Life Cycle Plan for the US and EU.